ADARx Pharmaceuticals develops a modality-agnostic RNA targeting platform that utilizes base editing of mRNA transcripts to create therapeutics for genetic, cardiometabolic, and central nervous system diseases. The company aims to provide effective treatments for intractable diseases by leveraging oligonucleotides for inhibition, degradation, and editing, along with advanced delivery technologies.

Arrivent is a clinical‑stage biopharmaceutical company that identifies, develops, and commercializes differentiated oncology medicines, focusing on hard‑to‑treat cancers. It leverages deep drug‑development and regulatory expertise to advance high‑quality candidates—including next‑generation antibody‑drug conjugates—through in‑licensing, partnerships, and strategic collaborations, aiming to bring effective therapies to global patients.

Arvinas uses a proprietary PROTAC discovery engine to design bifunctional molecules that recruit E3 ubiquitin ligases and trigger proteasomal degradation of disease‑relevant proteins, expanding the druggable proteome for oncology and neurodegenerative indications. The company advances clinical‑stage degraders and offers partnership models for pharmaceutical and biotechnology companies to co‑develop or license these targeted protein‑degradation therapeutics.

CG Oncology develops Cretostimogene, an intravesically delivered oncolytic immunotherapy for non‑muscle invasive bladder cancer (NMIBC). The therapy uses a genetically engineered virus to directly lyse tumor cells and stimulate a systemic immune response, aiming to reduce recurrence and preserve the bladder. It is being evaluated in a comprehensive clinical program for safety and efficacy, targeting urologists, oncologists, and healthcare systems seeking bladder‑sparing treatments.

Develops a pipeline of injectable and oral therapies, including GLP-1/GIP receptor dual agonists and oral small molecule GLP-1 agonists, for chronic weight management and type 2 diabetes. These therapies aim to provide differentiated treatment options backed by clinical evidence from multiple trials, addressing the growing prevalence of obesity and its related metabolic conditions.